THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that Neil K. Warma, Opexa’s President and Chief Executive Officer, has been invited to join several panel discussions in upcoming conferences in May. These include:

• China - U.S. Biopharmaceutical Innovative Collaboration Forum- May 13, 2015, Los Angeles, California, Hilton Los Angeles Airport Hotel
  
  10:30 a.m. – 11:20 a.m.: Mr. Warma will moderate a panel discussion entitled, “Strategies taken by China and U.S. government for encouraging biopharmaceutical R & D.”

• Texas Life Science Forum- May 20, 2015, Houston, Texas, Rice University BioScience Research Collaborative
  
  4:30 p.m. - 5:00 p.m.: Mr. Warma will moderate a panel discussion entitled, “From Preclinical to Phase III- Developing a Successful Clinical Development Program."

• Boston CEO Biotechnology Conference- May 26-27, 2015, Boston, Massachusetts, The Four Seasons Hotel
  
  1:30 p.m. – 2:00 p.m.: Mr. Warma will present as part of a panel discussion entitled, “The Importance of Patient Advocacy.”

• Marcum Microcap Conference- May 27-28, 2015, New York, New York, Grand Hyatt New York Hotel
  
  10:00 a.m. - 11:00 a.m.: Mr. Warma will present as part of a panel discussion entitled, “Discovering Breakthrough Opportunities in Life Sciences, How to Evaluate Early Stage and Pre-Revenue Life Science Companies.”

About Opexa

Opexa is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases such as neuromyelitis optica (NMO). These therapies are based on Opexa’s proprietary T-cell technology. The Company’s leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of secondary progressive MS. Tcelna consists of myelin-reactive T-cells, which are expanded ex vivo from the patient’s peripheral blood and reintroduced into the patient in an attenuated form via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin for each individual patient.

For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com.

Source: Opexa Therapeutics, Inc.